An independent guide to cash-pay care. Every price is dated and sourced.

How we check
Wellchosen Health

BPC-157: Legal Status, Evidence and Risks

BPC-157 is not an FDA-approved drug, and as of Oct 19, 2026 a US pharmacy may not lawfully compound it [2]. An FDA advisory committee voted 8 to 6, with 1 abstention, on July 23, 2026 to recommend allowing it, but the vote is not binding and FDA has not acted [7] [9]. FDA's own review found five small human studies and said there is not enough clinical safety information to describe its safety profile [1].

Updated By the Wellchosen Health editorial team

Medical review: pending. A licensed clinician has not yet reviewed this page.

BPC-157, also called Body Protection Compound 157 or PL 14736, is a peptide studied mostly in animals that has no FDA approval for any use [1] [3].

At a glance

Human studies FDA found
5 small studiesPlus 1 registered trial with no posted results [1]
Sports (WADA)
Banned at all timesClass S0 on the 2026 list [11]
FDA-approved products
NoneWe found no approved drug that contains BPC-157

See which peptides are legal

This page separates three questions that sellers often blur together: whether BPC-157 is legal, what the studies actually tested, and what is known about its safety. The status box below is checked against FDA sources and changes when FDA acts.

Legal status of BPC-157

Waiting on FDA after a favorable vote

BPC-157 won a favorable but nonbinding advisory committee vote in July 2026, and FDA has not acted on it [9]. It still cannot be legally compounded or sold as a drug [2].

FDA status
FDA removed it from Category 2 in April 2026 because the nominators withdrew their nominations [21]. That removal did not make it legal to compound [8]. FDA now lists it as "nominated but withdrawn," which is outside every category [17]. It is not in Category 1 and is not on the 503A bulks list, so a 503A pharmacy may not lawfully compound it today [2]. FDA's briefing says there is not enough clinical safety information to describe its safety profile, and no carcinogenicity studies are available [1].
Advisory committee
On July 23, 2026, the committee voted 8 yes, 6 no and 1 abstain to recommend adding BPC-157 to the 503A bulks list [7] [6]. The committee reviewed it for ulcerative colitis [23]. FDA staff had recommended against listing it [1]. FDA has not posted its own vote count on the meeting page [23]. Advisory committee votes are not binding. Nothing changes until FDA acts [10].
FDA-approved products
None. We found no FDA-approved drug that contains BPC-157.
Sports (WADA)
Prohibited at all times under class S0 (non-approved substances). BPC-157 is named as an example [11].
What happens next
To add it to the 503A bulks list, FDA must go through notice-and-comment rulemaking, starting with a proposed rule. FDA could also place it in Category 1 or announce enforcement discretion in the meantime [10]. As of Oct 16, 2026, FDA had not started rulemaking or moved any of these peptides to Category 1 [9]. HHS has sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House budget office for review. Holland & Knight dates that submission Oct 14, 2026 [9], while the AP reported it appeared on a government website on Oct 15 [22]. The policy has not been issued and its text is not public [9]. The AP, citing two unnamed people familiar with the plan, reported that it is meant to let pharmacies temporarily compound some of the most popular peptides, including BPC-157 [22]. Holland & Knight says the details are unknown [9]. One law firm says there is no reliable timetable for final action [10].

Checked against FDA sources on . We update this box when FDA acts. Report a change: [email protected].

What BPC-157 is

BPC-157 is a peptide also called Body Protection Compound 157 and PL 14736. Almost everything published about it comes from animal and lab work. A 2025 systematic review of its use in orthopedic and sports medicine included 36 studies: 35 were preclinical and 1 was a clinical study [3].

Online, BPC-157 is often paired with TB-500 and sold as a "Wolverine" stack. Healthline says the pair has been dubbed the "Wolverine" stack for its supposed regenerative effects, and that it "isn't approved by the FDA and hasn't been tested in humans for safety or effectiveness" [15]. Four-peptide blends sold under the name KLOW are covered on our KLOW page. For every peptide FDA is tracking, see the peptide FDA status tracker.

No, not as a drug for people. Under federal law, a 503A compounding pharmacy may use a bulk substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [19]. BPC-157 has none of these [2]. FDA also does not act against pharmacies using substances in its interim Category 1 while it decides on them, and BPC-157 has never been in Category 1 [20].

In April 2026, FDA gave seven days' notice that it would take 12 peptides, BPC-157 among them, out of Category 2, the group it flags for significant safety risks, because the companies that nominated them withdrew [21]. Frier Levitt, a pharmacy law firm, put the result plainly: "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A" [8]. FDA now lists BPC-157 as nominated but withdrawn [17].

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no and 1 abstain to recommend adding BPC-157 to the bulks list, for ulcerative colitis [7]. FDA staff had recommended against it [1]. At the meeting, FDA's Russell Wesdyk said quality standards for it cannot be set, while committee member David Pope said he voted yes because "it's time to put this decision back in the hands of the physician and pharmacist" [6]. The vote is advice only. FDA would still have to write a rule, place it in Category 1, or announce enforcement discretion, and one law firm says there is no reliable timetable [10].

In mid-October 2026, HHS sent an interim peptide access policy to the White House budget office for review [9]. The AP, citing two unnamed people familiar with the plan, reported that it is meant to let pharmacies temporarily compound some of the most popular peptides, including BPC-157 [22]. The policy has not been issued, and Holland & Knight says its details remain to be seen [9].

Does a prescription make it legal?

No. The limit is on the substance, not the paperwork. Until BPC-157 meets one of the 503A conditions or FDA places it in Category 1, a pharmacy may not lawfully compound it even with a prescription [2] [19].

Research use only labels

Vials labeled "research use only" or "not for human consumption" are not a legal route. FDA rejected that label in a Feb 26, 2025 warning letter to USApeptide.com, which sold semaglutide and tirzepatide with bacteriostatic water and syringes [14]. Arent Fox Schiff notes that FDA's Aug 24, 2026 letters to peptide sellers did not cite any of the six peptides the committee backed in July, BPC-157 included [18]. That is a choice of targets, not a legal green light. In April 2026, a federal grand jury in Utah indicted a physician on charges of receiving misbranded drugs from China, including BPC-157, TB-500 and GLP-1s, and giving them to more than 200 patients. Those are allegations, and he is presumed innocent [13]. More cases: FDA warning letters.

What the BPC-157 evidence shows

Human studies FDA found

FDA's May 2026 briefing for the advisory committee found five clinical studies plus one registered Phase 1 trial (NCT02637284) with no posted results [1]:

  • A rectal enema study in 24 healthy volunteers [1].
  • An ulcerative colitis enema trial with 53 people randomized, reported only as a 2005 meeting abstract [1].
  • Knee injections in 17 people [1].
  • Bladder instillation for interstitial cystitis in 12 people, published in 2024 [1].
  • An IV infusion in 2 healthy people, published in 2025 [1].

None of these is a completed, fully published randomized controlled trial. FDA's conclusion: "There is insufficient clinical safety information to characterize the safety profile of BPC-157" [1]. None of the studies FDA listed tested a pill or a nasal spray, two forms people often search for.

Animal and lab findings

The 2025 orthopedic review found that nearly all results come from preclinical animal and lab studies. Its single clinical study was a retrospective report on 12 people with knee pain, 7 of whom reported improvement over 6 months, with no comparison group. FDA describes what appears to be the same knee study as having 17 people [1] [3]. The review's own conclusion: "clinical safety in humans remains unknown" [3].

FDA also reviewed animal safety data. In 28-day injection studies in rats and dogs, FDA saw findings that appeared linked to clinically relevant safety signals, including changes in blood clotting measures and liver-related signals. BPC-157 was not mutagenic in standard tests, and no studies of cancer-causing potential were available [1].

The cancer and blood vessel debate

In lab and animal work, BPC-157 has pro-angiogenic effects, meaning it promotes new blood vessel growth. A 2025 literature and patent review by Józwiak and colleagues argued that this could be risky when cancer is present but undiagnosed, writing that BPC 157 "may not be the right choice, especially in situations where we are not aware of the presence of cancer cells in our body" [4]. The Zagreb group that first developed BPC-157 published a rebuttal the same year, citing animal and lab data they say show "prominent anti-tumor potential" [5]. FDA's briefing does not treat angiogenesis as a proven risk, but it notes that no carcinogenicity studies exist [1]. Neither side has human cancer data.

Immune reactions

FDA wrote that "BPC-157 may pose a significant risk for immunogenicity, potentially amplified by aggregation," meaning the body could mount an immune response to it. FDA says that response may be stronger when it is injected under the skin or used in the nose, and that it has never been formally studied [1].

BPC-157 side effects and risks

No study large enough to give reliable side effect rates exists. Lists of BPC-157 side effects on seller sites are not drawn from controlled data. What FDA has named are risks, not rates: possible immune reactions, clotting and liver signals in animal studies, unknown cancer potential, and no way to set quality standards [1] [6].

Use is rising anyway. Reuters reported in September 2026 on an analysis by the data firm nference of more than 15 million US medical records: it found 1,039 patients with documented BPC-157 use and a 33-fold rise in new confirmed users from 2020 to 2026. The analysis had not been peer reviewed. The report quoted this comment: "Most likely, very few doctors are even asking their patients, 'Are you taking BPC-157?'" [12].

If you have used BPC-157

Tell your doctor and pharmacist, and mention it before any surgery. FDA noted clotting and liver signals in animal studies, and its cancer potential is unknown [1]. Hives, swelling of the face, lips or throat, or trouble breathing after an injection need emergency care. Call 911.

Injections, pills and nasal sprays

People search for BPC-157 injections, pills and nasal sprays. FDA has reviewed none of these forms as a drug, and none is legal to compound [2]. The human studies FDA found used enemas, knee injections, bladder instillation and IV infusion, not pills or sprays [1]. FDA flags under-the-skin injection and nasal use as carrying a higher immune reaction risk [1]. So the question "oral or injection?" has no evidence-based answer, and neither does the question of when to take it.

BPC-157 dosage: why we do not give one

There is no FDA-reviewed dose of BPC-157. The doses, cycles and vial sizes sold online, such as 10 mg vials, come from research chemical marketing, not from a reviewed clinical program. FDA's 2026 review found too little human data even to describe its safety [1]. We do not publish dosing, mixing or injection instructions for unapproved peptides. For approved drugs, the product label and your prescriber are the only dosing sources.

BPC-157 and drug testing in sports

BPC-157 is prohibited at all times on the World Anti-Doping Agency's 2026 list, under class S0 for non-approved substances. The list names it: "This class covers many different substances including but not limited to BPC-157" [11]. That applies in and out of competition.

How to get BPC-157 legally

There is no legal way to buy BPC-157 today

There is no legal way to buy BPC-157 for human use in the US today. A 503A pharmacy may not compound it, and no FDA-approved drug contains it [2]. Products labeled "research use only" are not a legal workaround; FDA has rejected that label in warning letters to online sellers [14].

If you are looking at BPC-157 for an injury, joint pain or a gut condition, a doctor can talk through FDA-approved treatments for the diagnosis. If you are comparing peptides that can be legally prescribed today, see our legal peptide price tracker, the FDA-approved peptide tesamorelin, and our guide to wellness injections. For GLP-1 peptides sold as research chemicals, see research-use-only GLP-1s and our retatrutide page.

What changed for BPC-157

Newest first. Each entry links to its source.

  • : HHS sent an interim peptide access policy to the White House budget office for review, per Holland & Knight [9]. The AP reported it appeared on Oct 15 [22]. It has not been issued [9].
  • : On July 23, 2026, the committee voted 8 yes, 6 no and 1 abstain to recommend adding BPC-157 to the 503A bulks list [7] [6].
  • : FDA staff briefing documents recommended against adding it to the 503A bulks list [1].
  • : The removal took effect around this date. FDA now lists it as nominated but withdrawn, which does not allow compounding [17] [8].
  • : FDA gave seven days' notice that it would remove 12 peptides, including this one, from Category 2 because the nominators withdrew [21].
  • : FDA placed it in Category 2, citing significant safety risks [24].

How we check

We read FDA's 503A categories document, FDA's briefing documents and meeting pages, and the 2026 WADA list, and we cross-check committee vote counts against at least two law firm or trade reports because FDA has not posted its own minutes for the July 2026 meeting [7] [6]. We do not cite or link sellers. The status box was last checked on Oct 19, 2026. When FDA acts, we update the status file, and this page changes with it. Our method is in our editorial standards.

Questions people ask

What are the benefits of BPC-157?

No benefit has been shown in a completed, fully published human trial. FDA's May 2026 review found five small human studies, the largest a 53-person ulcerative colitis trial reported only as a 2005 meeting abstract, and said there is not enough clinical safety information to describe its safety profile [1]. Claims about healing tendons, joints and the gut come mainly from rat studies; a 2025 review counted 35 preclinical studies and 1 clinical study [3].

What are the side effects of BPC-157?

No reliable side effect rates exist, because no large controlled human trial has been published. FDA's 2026 briefing named possible risks instead: immune reactions (possibly stronger with under-the-skin injection and nasal use), changes in clotting and liver signals in 28-day rat and dog studies, and no data on cancer-causing potential [1].

Is BPC-157 legal?

Not for human use in the US as of Oct 19, 2026. It is not in FDA's Category 1 or on the 503A bulks list, so a pharmacy may not lawfully compound it, and no FDA-approved drug contains it [2]. An advisory committee voted 8-6-1 in favor on July 23, 2026, but the vote is nonbinding and FDA has not acted [7] [10].

Is BPC-157 safe?

No regulator has found it safe. FDA wrote in May 2026 that "there is insufficient clinical safety information to characterize the safety profile of BPC-157," and that no carcinogenicity studies are available [1]. FDA staff recommended against adding it to the compounding list [1].

Does BPC-157 cause cancer?

No one knows, because no carcinogenicity studies exist, according to FDA [1]. A 2025 review argued its effect on blood vessel growth could be risky if cancer is present but undiagnosed [4]; the group that developed it published a rebuttal citing animal data it says show anti-tumor effects [5]. Neither side has human cancer data.

Are there real BPC-157 before and after results?

Not from controlled trials. The only clinical study in a 2025 orthopedic review was a retrospective report in which 7 of 12 people with knee pain said they improved over 6 months, with no comparison group [3]. Before and after photos and stories on seller sites are not evidence.

Is oral BPC-157 better than injections?

There is no evidence either way. None of the human studies FDA found in 2026 tested a pill or a nasal spray; they used enemas, knee and IV injections and bladder instillation [1]. No form of BPC-157 has been reviewed by FDA, and FDA says immune reaction risk may be higher for under-the-skin injection and nasal use [1].

What is the BPC-157 dosage?

There is no FDA-reviewed dose of BPC-157. Doses and vial sizes sold online come from research chemical marketing, not a reviewed clinical program, and FDA's 2026 briefing found too little human data to describe its safety [1]. For FDA-approved drugs, the product label and your prescriber are the only dosing sources.

What is the difference between BPC-157 and TB-500?

Both were on the July 23, 2026 committee agenda and both got the same 8-6-1 nonbinding vote, and neither can be compounded today [7] [2]. The evidence differs: FDA found five small human studies of BPC-157 [1], but no clinical studies, no human drug level data and no published case reports for TB-500 [16].

Is BPC-157 banned by WADA?

Yes. The 2026 WADA Prohibited List bans BPC-157 at all times under class S0, non-approved substances, and names it as an example [11].

Sources

24 cited
  1. PCAC briefing document: BPC-157. FDA, May 11, 2026.
  2. Bulk drug substances nominated for use in compounding under section 503A (categories document). FDA, May 14, 2026.
  3. Systematic review of BPC-157 in orthopedic and sports medicine (PMID 40756949). HSS Journal (Vasireddi et al.), Jul 31, 2025.
  4. Literature and patent review of BPC 157. Pharmaceuticals (Józwiak et al.), Jan 30, 2025.
  5. Reply on BPC 157 and tumor concerns. Pharmaceuticals (Sikiric et al.), 2025;18(10):1450, Oct 2025.
  6. FDA advisory committee backs two controversial peptides. RAPS Regulatory Focus, Jul 23, 2026.
  7. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. McDermott Will & Emery, Jul 2026.
  8. FDA peptides do-not-compound list update (2026). Frier Levitt, Apr 2026.
  9. Peptides at a crossroads: what wellness providers need to know. Holland & Knight, Oct 16, 2026.
  10. FDA voted yes on six peptides. Now what? The regulatory road ahead. Buchanan Ingersoll & Rooney, Aug 18, 2026.
  11. 2026 Prohibited List. World Anti-Doping Agency (copy hosted by Asia Rugby), Sep 2025.
  12. Use of untested 'Wolverine' peptide backed by US health secretary Kennedy on the rise, study finds. Reuters (via Hawaii Tribune-Herald), Sep 16, 2026.
  13. Utah licensed osteopathic physician indicted for allegedly receiving misbranded drugs from China. U.S. Attorney's Office, District of Utah, Apr 2026.
  14. Warning letter: USApeptide.com. FDA, Feb 26, 2025.
  15. Wolverine peptides (BPC-157 and TB-500). Healthline, Oct 14, 2026.
  16. PCAC briefing document: TB-500. FDA, May 15, 2026.
  17. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA, Apr 22, 2026.
  18. RUO-ined: five peptide vendors learn research use only is not a legal strategy. Arent Fox Schiff, Aug 2026.
  19. Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA, May 14, 2026.
  20. FDA's peptide rally: what compounders and industry need to know (post 1 of 2). Hyman, Phelps & McNamara (FDA Law Blog), Apr 21, 2026.
  21. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings. Orrick, Apr 16, 2026.
  22. Trump administration advances plan for peptide drugs favored by RFK Jr.. STAT (Associated Press), Oct 15, 2026.
  23. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. FDA, Jul 23, 2026.
  24. 503A categories update, September 2023. FDA (hosted by Alliance for Pharmacy Compounding), Sep 29, 2023.

This page is general information, not medical advice. Talk with a licensed clinician about your own care.

See which peptides are legal